HHS awards $64M for COVID-19 research, with PPD Development LP securing a Cost Plus Fixed Fee contract

Contract Overview

Contract Amount: $64,031,927 ($64.0M)

Contractor: PPD Development LP

Awarding Agency: Department of Health and Human Services

Start Date: 2022-11-06

End Date: 2025-08-31

Contract Duration: 1,029 days

Daily Burn Rate: $62.2K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: "COVID 19"COMPLETION OF ACTIV 2 STUDY

Place of Performance

Location: WILMINGTON, NEW HANOVER County, NORTH CAROLINA, 28401

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $64.0 million to PPD DEVELOPMENT LP for work described as: "COVID 19"COMPLETION OF ACTIV 2 STUDY Key points: 1. Contract value of $64M for a 3-year research and development effort. 2. Competition was full and open, suggesting a potentially competitive bidding process. 3. The contract type is Cost Plus Fixed Fee, which can lead to cost overruns if not managed carefully. 4. Performance is in North Carolina, with an end date of August 2025. 5. The contract falls under the Biotechnology R&D sector, a critical area for public health. 6. No small business set-aside was utilized, indicating a focus on larger, specialized contractors.

Value Assessment

Rating: fair

The contract value of $64M for a 3-year research project appears within a reasonable range for complex biotechnology R&D. However, the Cost Plus Fixed Fee (CPFF) structure introduces inherent risk. While it allows for flexibility in research, it can incentivize cost increases if the fixed fee is not carefully calibrated against anticipated expenses. Benchmarking against similar NIH-funded R&D contracts for COVID-19 research would provide a clearer picture of value for money, but initial assessment suggests it's within expected parameters for this type of specialized work.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that all responsible sources were permitted to submit bids. The number of bidders is not specified, but this approach generally fosters a competitive environment, which can lead to better pricing and innovation. The agency's decision to use full and open competition suggests confidence in the market's ability to provide qualified contractors for this specialized research.

Taxpayer Impact: Taxpayers benefit from the potential for competitive pricing and the assurance that the government sought the best value through an open process.

Public Impact

The primary beneficiaries are public health initiatives aimed at combating COVID-19 through advanced research. The contract supports critical research and development activities in biotechnology. Geographic impact is focused on North Carolina, where the contractor is located. Workforce implications include employment for researchers, scientists, and support staff at PPD Development LP.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Cost Plus Fixed Fee contracts can lead to higher overall costs if not closely monitored.
Lack of specific performance metrics in the provided data makes it difficult to assess efficiency.
The duration of the contract (over 3 years) requires sustained oversight to ensure objectives are met.

Positive Signals

Awarded under full and open competition, suggesting a robust selection process.
Contractor PPD Development LP is likely experienced in biotechnology R&D.
Focus on COVID-19 research aligns with critical national health priorities.

Sector Analysis

This contract falls within the Biotechnology Research and Development sector, a rapidly evolving field critical for public health advancements. The market for such services is characterized by high specialization, significant investment in infrastructure and talent, and often involves collaboration with government agencies like the NIH. Comparable spending benchmarks would typically involve other large-scale R&D grants and contracts awarded by NIH and other health-focused federal bodies for infectious disease research and vaccine development.

Small Business Impact

The absence of a small business set-aside for this contract suggests that the scope of work likely requires the resources and expertise typically found in larger, established research organizations. While this specific contract may not directly benefit small businesses through a set-aside, PPD Development LP may engage small businesses as subcontractors, contributing indirectly to the small business ecosystem. Further analysis of subcontracting plans would be needed to confirm this impact.

Oversight & Accountability

Oversight for this contract would primarily reside with the National Institutes of Health (NIH), a component of HHS. Mechanisms likely include regular progress reports, financial reviews, and potentially site visits to ensure compliance with the contract terms and research protocols. The CPFF structure necessitates close monitoring of expenditures to ensure costs are reasonable and allocable to the contract. Transparency is generally maintained through contract databases, though specific research findings are subject to publication and dissemination policies.

Related Government Programs

COVID-19 Research Grants
Biotechnology Research and Development Contracts
National Institutes of Health Research Programs
Public Health Emergency Response Funding

Risk Flags

Cost Plus Fixed Fee contract type may lead to cost overruns.
Research and Development projects inherently carry scientific uncertainty.
Long contract duration requires sustained oversight.
Potential for scope creep in R&D projects.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $64.0 million to PPD DEVELOPMENT LP. "COVID 19"COMPLETION OF ACTIV 2 STUDY

Who is the contractor on this award?

The obligated recipient is PPD DEVELOPMENT LP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $64.0 million.

What is the period of performance?

Start: 2022-11-06. End: 2025-08-31.

What is the track record of PPD Development LP in securing and performing on federal R&D contracts, particularly with HHS/NIH?

PPD Development LP, now part of Thermo Fisher Scientific, has a significant history of performing federal research and development contracts. While specific details on their track record with HHS/NIH for COVID-19 related work require deeper database searches, the company is a well-established Contract Research Organization (CRO) with extensive experience in clinical trials, drug development, and laboratory services. Their ability to secure a $64M contract from NIH indicates a strong existing relationship and a proven capability to meet the rigorous requirements of federal health research. Past performance evaluations and award histories would provide a more granular view of their success rates, adherence to timelines, and budget management on similar government projects.

How does the Cost Plus Fixed Fee (CPFF) structure compare to other contract types for similar R&D projects in terms of cost efficiency?

The Cost Plus Fixed Fee (CPFF) contract type is often used for research and development where the scope of work is not precisely defined at the outset, allowing for flexibility as the project evolves. Compared to Firm-Fixed-Price (FFP) contracts, CPFF offers less cost certainty for the government, as the final cost is the actual allowable cost plus a pre-negotiated fixed fee. FFP contracts provide greater cost predictability but can be risky if the scope is underestimated, potentially leading to contractor claims or reduced quality. Cost-Plus-Incentive-Fee (CPIF) contracts offer a middle ground, sharing cost savings or overruns between the government and contractor. For R&D, CPFF can be efficient if the government maintains strong oversight to control costs, but it carries a higher risk of exceeding initial budget estimates than FFP.

What are the key performance indicators (KPIs) used to measure the success of this COVID-19 research contract?

While the provided data does not specify the Key Performance Indicators (KPIs) for this particular contract, typical metrics for NIH-funded R&D projects in biotechnology often include: achievement of specific research milestones (e.g., identification of therapeutic targets, development of vaccine candidates, completion of preclinical studies), timely delivery of research reports and data, adherence to scientific protocols and quality standards, and successful publication of findings in peer-reviewed journals. For a COVID-19 research contract, KPIs would likely be tied to advancing the understanding of the virus, developing countermeasures, or improving diagnostic capabilities, all within defined timelines and budget constraints. The fixed fee component of the CPFF contract implies that certain performance expectations are implicitly understood and factored into the fee.

What is the historical spending trend for similar biotechnology R&D contracts awarded by the National Institutes of Health?

Historical spending trends for similar biotechnology R&D contracts awarded by the National Institutes of Health (NIH) show a consistent and significant investment, particularly in areas of emerging public health concern like infectious diseases. NIH is the largest public funder of biomedical research in the world, with annual budgets in the tens of billions of dollars. Spending on R&D contracts and grants related to virology, immunology, and vaccine development has seen substantial increases, especially following major outbreaks like COVID-19. While the $64M for this specific contract is a notable amount, it is within the range of large-scale, multi-year R&D initiatives funded by NIH. Analyzing NIH's budget allocations and contract award databases over the past decade would reveal a pattern of increasing investment in cutting-edge biotechnology to address national and global health challenges.

Are there any specific risks associated with the 'Research and Development in Biotechnology (except Nanobiotechnology)' category that warrant attention for this contract?

Yes, the 'Research and Development in Biotechnology (except Nanobiotechnology)' category carries inherent risks typical of cutting-edge scientific endeavors. These include scientific uncertainty, where research outcomes may not materialize as expected or may prove inconclusive. There's also the risk of technological obsolescence, where advancements in the field could render the current research approach outdated. Regulatory hurdles are common, as biotechnology research often faces stringent ethical and safety reviews. Furthermore, the long lead times and high costs associated with bringing biotechnological innovations to market, coupled with potential intellectual property disputes, represent significant financial and operational risks. For this specific COVID-19 contract, the urgency of the pandemic may have accelerated timelines, potentially increasing risks related to thoroughness and validation.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 2023-01

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 929 N FRONT ST, WILMINGTON, NC, 28401

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $64,031,927

Exercised Options: $64,031,927

Current Obligation: $64,031,927

Actual Outlays: $63,130,077

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Parent Contract

Parent Award PIID: 75N93021D00035

IDV Type: IDC

Timeline